AMENDMENT NO. 1 TO At-THE-market issuance SALES AGREEMENTAt-the-Market Issuance Sales Agreement • May 7th, 2018 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York
Synthetic Biologics, Inc. (the “Company”) and FBR Capital Markets & Co. (“FBR”) are parties to that certain At-the-Market Issuance Sales Agreement dated August 5, 2016 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, together with B. Riley FBR, Inc. (“B. Riley FBR”), intending to be legally bound, hereby amend the Original Agreement as follows:
